Occudo Quantitative Strategies LP Nektar Therapeutics Transaction History

Occudo Quantitative Strategies LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.51 - $1.05 $61,922 - $127,486	-121,416 Reduced 80.86%	28,738 $17,000
Q1 2023 May 15, 2023	SELL	$0.64 - $3.15 $61,419 - $302,299	-95,968 Reduced 38.99%	150,154 $105,000
Q4 2022 Feb 14, 2023	SELL	$2.03 - $4.28 $133,949 - $282,415	-65,985 Reduced 21.14%	246,122 $556,000
Q3 2022 Nov 14, 2022	BUY	$3.04 - $5.14 $65,718 - $111,116	21,618 Added 7.44%	312,107 $999,000
Q2 2022 Aug 15, 2022	BUY	$3.17 - $6.17 $599,928 - $1.17 Million	189,252 Added 186.94%	290,489 $1.1 Million
Q1 2022 May 16, 2022	BUY	$4.16 - $13.72 $284,552 - $938,475	68,402 Added 208.32%	101,237 $546,000
Q4 2021 Feb 14, 2022	SELL	$10.83 - $18.41 $53,326 - $90,650	-4,924 Reduced 13.04%	32,835 $444,000
Q3 2021 Nov 15, 2021	BUY	$13.07 - $18.84 $361,320 - $520,831	27,645 Added 273.33%	37,759 $678,000
Q2 2021 Aug 16, 2021	BUY	$16.52 - $20.4 $167,083 - $206,325	10,114 New	10,114 $174,000
Q1 2021 May 14, 2021	SELL	$16.56 - $25.46 $391,544 - $601,976	-23,644 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$15.77 - $19.03 $372,865 - $449,945	23,644 New	23,644 $402,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $171M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Occudo Quantitative Strategies LP, based on Form 13F filings with the SEC.

Stay updated on Occudo Quantitative Strategies LP with notifications on news.